BREVIBLOC- esmolol hydrochloride injection

BREVIBLOC by

Drug Labeling and Warnings

BREVIBLOC by is a Prescription medication manufactured, distributed, or labeled by Baxter Healthcare Corporation. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia

    BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC injection is intended for short-term use.

    1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension

    BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.

    Use of BREVIBLOC injection to prevent such events is not recommended.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosing for the Treatment of Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia

    BREVIBLOC injection is administered by continuous intravenous infusion with or without a loading dose. Additional loading doses and/or titration of the maintenance infusion (step-wise dosing) may be necessary based on desired ventricular response.

    Table 1 Step-Wise Dosing

    Step

    Action

    1

    Optional loading dose (500 mcg per kg over 1 minute), then 50 mcg per kg per min for 4 min

    2

    Optional loading dose if necessary, then 100 mcg per kg per min for 4 min

    3

    Optional loading dose if necessary, then 150 mcg per kg per min for 4 min

    4

    If necessary, increase dose to 200 mcg per kg per min

    In the absence of loading doses, continuous infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes.

    The effective maintenance dose for continuous and step-wise dosing is 50 to 200 mcg per kg per minute, although doses as low as 25 mcg per kg per minute have been adequate. Dosages greater than 200 mcg per kg per minute provide little added heart rate lowering effect, and the rate of adverse reactions increases.

    Maintenance infusions may be continued for up to 48 hours.

    2.2 Intraoperative and Postoperative Tachycardia and Hypertension

    In this setting it is not always advisable to slowly titrate to a therapeutic effect. Therefore two dosing options are presented: immediate control and gradual control.

    Immediate Control

    • Administer 1 mg per kg as a bolus dose over 30 seconds followed by an infusion of 150 mcg per kg per min if necessary.
    • Adjust the infusion rate as required to maintain desired heart rate and blood pressure. Refer to Maximum Recommended Doses below.

    Gradual Control

    • Administer 500 mcg per kg as a bolus dose over 1 minute followed by a maintenance infusion of 50 mcg per kg per min for 4 minutes.
    • Depending on the response obtained, continue dosing as outlined for supraventricular tachycardia. Refer to Maximum Recommended Doses below.

    Maximum Recommended Doses

    • For the treatment of tachycardia, maintenance infusion dosages greater than 200 mcg per kg per min are not recommended; dosages greater than 200 mcg per kg per min provide little additional heart rate-lowering effect, and the rate of adverse reactions increases.
    • For the treatment of hypertension, higher maintenance infusion dosages (250-300 mcg per kg per min) may be required. The safety of doses above 300 mcg per kg per minute has not been studied.

    2.3 Transition from BREVIBLOC Injection Therapy to Alternative Drugs

    After patients achieve adequate control of the heart rate and a stable clinical status, transition to alternative antiarrhythmic drugs may be accomplished.

    When transitioning from BREVIBLOC injection to alternative drugs, the physician should carefully consider the labeling instructions of the alternative drug selected and reduce the dosage of BREVIBLOC injection as follows:

    • 1. Thirty minutes following the first dose of the alternative drug, reduce the BREVIBLOC infusion rate by one-half (50%).
    • 2. After administration of the second dose of the alternative drug, monitor the patient’s response and if satisfactory control is maintained for the first hour, discontinue the BREVIBLOC infusion.

    2.4 Directions for Use

    BREVIBLOC injection is available in a pre-mixed bag and ready-to-use vial. BREVIBLOC injection is not compatible with Sodium Bicarbonate (5%) solution (limited stability) or furosemide (precipitation).

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    Premixed Bag

    • The medication port is to be used solely for withdrawing an initial bolus from the bag.
    • Use aseptic technique when withdrawing the bolus dose.
    • Do not add any additional medications to the bag.
    Figure 1: Two-port INTRAVIA Bag

    Figure 1: Two-Port INTRAVIA Bag

    Ready-to-Use Vial

    The Ready-to-use Vial may be used to administer a loading dosage by hand-held syringe while the maintenance infusion is being prepared [see How Supplied/Storage and Handling (16.2)].

    Compatibility with Commonly Used Intravenous Fluids

    BREVIBLOC injection was tested for compatibility with ten commonly used intravenous fluids at a final concentration of 10 mg esmolol hydrochloride per mL. BREVIBLOC injection was found to be compatible with the following solutions and was stable for at least 24 hours at controlled room temperature or under refrigeration:

    • Dextrose (5%) Injection, USP
    • Dextrose (5%) in Lactated Ringer’s Injection
    • Dextrose (5%) in Ringer’s Injection
    • Dextrose (5%) and Sodium Chloride (0.45%) Injection, USP
    • Dextrose (5%) and Sodium Chloride (0.9%) Injection, USP
    • Lactated Ringer’s Injection, USP
    • Potassium Chloride (40 mEq/liter) in Dextrose (5%) Injection, USP
    • Sodium Chloride (0.45%) Injection, USP
    • Sodium Chloride (0.9%) Injection, USP
  • 3 DOSAGE FORMS AND STRENGTHS

    All BREVIBLOC injection dosage forms are iso-osmotic solutions of esmolol hydrochloride in sodium chloride.

    Table 2 BREVIBLOC Injection Presentations

    Product Name

    BREVIBLOC

    PREMIXED Injection

    (Esmolol Hydrochloride)

    BREVIBLOC

    PREMIXED Double Strength Injection

    (Esmolol Hydrochloride)

    BREVIBLOC Injection

    (Esmolol Hydrochloride)

    Total Dose

    2500 mg / 250 mL

    2000 mg / 100 mL

    100 mg / 10 mL

    Esmolol Hydrochloride Concentration

    10 mg/mL

    20 mg/mL

    10 mg/mL

    Packaging

    250 mL Bag

    100 mL Bag

    10 mL Vial
  • 4 CONTRAINDICATIONS

    BREVIBLOC (Esmolol Hydrochloride) injection is contraindicated in patients with:

    • Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
    • Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
    • Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
    • Decompensated heart failure: May worsen heart failure.
    • Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.
    • IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC injection in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC injection and intravenous verapamil.
    • Pulmonary hypertension: May precipitate cardiorespiratory compromise.
    • Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypotension

    Hypotension can occur at any dose but is dose-related. Patients with hemodynamic compromise or on interacting medications are at particular risk. Severe reactions may include loss of consciousness, cardiac arrest, and death. For control of ventricular heart rate, maintenance doses greater than 200 mcg per kg per min are not recommended. Monitor patients closely, especially if pretreatment blood pressure is low. In case of an unacceptable drop in blood pressure, reduce or stop BREVIBLOC injection. Decrease of dose or termination of infusion reverses hypotension, usually within 30 minutes.

    5.2 Bradycardia

    Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest have occurred with the use of BREVIBLOC injection. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders may be at increased risk. Monitor heart rate and rhythm in patients receiving BREVIBLOC injection [see Contraindications (4)].

    If severe bradycardia develops, reduce or stop BREVIBLOC injection.

    5.3 Cardiac Failure

    Beta blockers, like BREVIBLOC injection, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. At the first sign or symptom of impending cardiac failure, stop BREVIBLOC injection and start supportive therapy [see Overdosage (10)].

    5.4 Intraoperative and Postoperative Tachycardia and/or Hypertension

    Monitor vital signs closely and titrate BREVIBLOC injection slowly in the treatment of patients whose blood pressure is primarily driven by vasoconstriction associated with hypothermia.

    5.5 Reactive Airways Disease

    Patients with reactive airways disease should, in general, not receive beta blockers. Because of its relative beta1 selectivity and titratability, titrate BREVIBLOC injection to the lowest possible effective dose. In the event of bronchospasm, stop the infusion immediately; a beta2 stimulating agent may be administered with appropriate monitoring of ventricular rates.

    5.6 Use in Patients with Diabetes Mellitus and Hypoglycemia

    In patients with hypoglycemia, or diabetic patients (especially those with labile diabetes) who are receiving insulin or other hypoglycemic agents, beta blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be masked.

    Concomitant use of beta blockers and antidiabetic agents can enhance the effect of antidiabetic agents (blood glucose–lowering).

    5.7 Infusion Site Reactions

    Infusion site reactions have occurred with the use of BREVIBLOC injection. They include irritation, inflammation, and severe reactions (thrombophlebitis, necrosis, and blistering), in particular when associated with extravasation [see Adverse Reactions (6)]. Avoid infusions into small veins or through a butterfly catheter.

    If a local infusion site reaction develops, use an alternative infusion site and avoid extravasation.

    5.8 Use in Patients with Prinzmetal’s Angina

    Beta blockers may exacerbate anginal attacks in patients with Prinzmetal’s angina because of unopposed alpha receptor–mediated coronary artery vasoconstriction. Do not use nonselective beta blockers.

    5.9 Use in Patients with Pheochromocytoma

    If BREVIBLOC injection is used in the setting of pheochromocytoma, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta-mediated vasodilation in skeletal muscle.

    5.10 Use in Hypovolemic Patients

    In hypovolemic patients, BREVIBLOC injection can attenuate reflex tachycardia and increase the risk of hypotension.

    5.11 Use in Patients with Peripheral Circulatory Disorders

    In patients with peripheral circulatory disorders (including Raynaud’s disease or syndrome, and peripheral occlusive vascular disease), BREVIBLOC injection may aggravate peripheral circulatory disorders.

    5.12 Abrupt Discontinuation of BREVIBLOC Injection

    Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta blocker therapy. Observe patients for signs of myocardial ischemia when discontinuing BREVIBLOC injection.

    Heart rate increases moderately above pretreatment levels 30 minutes after BREVIBLOC injection discontinuation.

    5.13 Hyperkalemia

    Beta blockers, including BREVIBLOC injection, have been associated with increases in serum potassium levels and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment. Intravenous administration of beta blockers has been reported to cause potentially life-threatening hyperkalemia in hemodialysis patients. Monitor serum electrolytes during therapy with BREVIBLOC injection.

    5.14 Use in Patients with Metabolic Acidosis

    Beta blockers, including BREVIBLOC injection, have been reported to cause hyperkalemic renal tubular acidosis. Acidosis in general may be associated with reduced cardiac contractility.

    5.15 Use in Patients with Hyperthyroidism

    Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy.

    5.16 Use in Patients at Risk of Severe Acute Hypersensitivity Reactions

    When using beta blockers, patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic).

    Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions [see Drug Interactions (7)].

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

    The following adverse reaction rates are based on use of BREVIBLOC (Esmolol Hydrochloride) injection in clinical trials involving 369 patients with supraventricular tachycardia and over 600 intraoperative and postoperative patients enrolled in clinical trials. Most adverse effects observed in controlled clinical trial settings have been mild and transient. The most important and common adverse effect has been hypotension [see Warnings and Precautions (5.1)]. Deaths have been reported in post-marketing experience occurring during complex clinical states where BREVIBLOC injection was presumably being used simply to control ventricular rate [see Warnings and Precautions (5.5)].

    Table 3 Clinical Trial Adverse Reactions (Frequency ≥3%)
    System Organ Class (SOC)Preferred MedDRA TermFrequency

    VASCULAR DISORDERS

    Hypotension*
    •   Asymptomatic hypotension

    25%
    •   Symptomatic hypotension
      (hyperhidrosis, dizziness)

    12%

    GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS

    Infusion site reactions
    (inflammation and induration)

    8%

    GASTROINTESTINAL DISORDERS

    Nausea

    7%

    NERVOUS SYSTEM DISORDERS

    Dizziness

    3%

    Somnolence

    3%

    * Hypotension resolved during BREVIBLOC (Esmolol Hydrochloride) infusion in 63% of patients. In 80% of the remaining patients, hypotension resolved within 30 minutes following discontinuation of infusion.

    Clinical Trial Adverse Reactions (Frequency <3%)

    Psychiatric Disorders

    Confusional state and agitation (~2%)
    Anxiety, depression and abnormal thinking (<1%)

    Nervous System Disorders

    Headache (~ 2%)
    Paresthesia, syncope, speech disorder, and lightheadedness (<1%)
    Convulsions (<1%), with one death

    Vascular Disorders

    Peripheral ischemia (~1%)
    Pallor and flushing (<1%)

    Gastrointestinal Disorders

    Vomiting (~1%)
    Dyspepsia, constipation, dry mouth, and abdominal discomfort (<1%)

    Renal and Urinary Disorders

    Urinary retention (<1%)

    6.2 Post-Marketing Experience

    In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been reported in the post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.

    Cardiac Disorders

    Cardiac arrest, Coronary arteriospasm

    Skin and Subcutaneous Tissue Disorders

    Angioedema, Urticaria, Psoriasis

  • 7 DRUG INTERACTIONS

    Concomitant use of BREVIBLOC injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate BREVIBLOC injection’s effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below.) BREVIBLOC injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to:

    • Digitalis glycosides: Concomitant administration of digoxin and BREVIBLOC injection leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. Digoxin does not affect BREVIBLOC injection pharmacokinetics. Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use increases the risk of bradycardia.
    • Anticholinesterases: BREVIBLOC injection prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.
    • Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.
    • Calcium channel antagonists: In patients with depressed myocardial function, use of BREVIBLOC injection with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests.
    • Sympathomimetic drugs: Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of BREVIBLOC injection.
    • Vasoconstrictive and positive inotropic agents: Because of the risk of reducing cardiac contractility in presence of high systemic vascular resistance, do not use BREVIBLOC injection to control tachycardia in patients receiving drugs that are vasoconstrictive and have positive inotropic effects, such as epinephrine, norepinephrine, and dopamine.
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. BREVIBLOC injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions.

    8.2 Labor and Delivery

    Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. BREVIBLOC injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    8.3 Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BREVIBLOC injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    8.4 Pediatric Use

    The safety and effectiveness of BREVIBLOC injection in pediatric patients have not been established.

    8.5 Geriatric Use

    Clinical studies of BREVIBLOC injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy.

    8.6 Hepatic Impairment

    No special precautions are necessary in patients with hepatic impairment because BREVIBLOC injection is metabolized by red-blood cell esterases [see Clinical Pharmacology (12)].

    8.7 Renal Impairment

    No dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. There is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours [see Clinical Pharmacology (12)].

  • 10 OVERDOSAGE

    10.1 Signs and Symptoms of Overdose

    Overdoses of BREVIBLOC (Esmolol Hydrochloride) injection can cause cardiac and central nervous system effects. These effects may precipitate severe signs, symptoms, sequelae, and complications (for example, severe cardiac and respiratory failure, including shock and coma), and may be fatal. Continuous monitoring of the patient is required.

    • Cardiac effects include bradycardia, atrioventricular block (1st -, 2nd -, 3rd degree), junctional rhythms, intraventricular conduction delays, decreased cardiac contractility, hypotension, cardiac failure (including cardiogenic shock), cardiac arrest/asystole, and pulseless electrical activity.
    • Central nervous system effects include respiratory depression, seizures, sleep and mood disturbances, fatigue, lethargy, and coma.
    • In addition, bronchospasm, mesenteric ischemia, peripheral cyanosis, hyperkalemia, and hypoglycemia (especially in children) may occur.

    10.2 Treatment Recommendations

    Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the BREVIBLOC infusion. Then, based on the observed clinical effects, consider the following general measures.

    Bradycardia

    Consider intravenous administration of atropine or another anticholinergic drug or cardiac pacing.

    Cardiac Failure

    Consider intravenous administration of a diuretic or digitalis glycoside. In shock resulting from inadequate cardiac contractility, consider intravenous administration of dopamine, dobutamine, isoproterenol, or inamrinone. Glucagon has been reported to be useful.

    Symptomatic hypotension

    Consider intravenous administration of fluids or vasopressor agents such as dopamine or norepinephrine.

    Bronchospasm

    Consider intravenous administration of a beta2 stimulating agent or a theophylline derivative.

    10.3 Dilution Errors

    Massive accidental overdoses of BREVIBLOC injection have resulted from dilution errors. Use of BREVIBLOC PREMIXED Injection and BREVIBLOC PREMIXED Double Strength Injection may reduce the potential for dilution errors. Some of these overdoses have been fatal while others resulted in permanent disability. Bolus doses in the range of 625 mg to 2.5 g (12.5‑50 mg/kg) have been fatal. Patients have recovered completely from overdoses as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery. The patients who survived appear to be those whose circulation could be supported until the effects of BREVIBLOC injection resolved.

  • 11 DESCRIPTION

    BREVIBLOC injection (Esmolol Hydrochloride) is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:

    • (±)-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnamate hydrochloride and has the following structure:

    Esmolol hydrochloride Structural Formula

    • Esmolol hydrochloride has the empirical formula C16H26NO4Cl and a molecular weight of 331.8. It has one asymmetric center and exists as an enantiomeric pair.
    • Esmolol hydrochloride is a white to off-white crystalline powder. It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.

    11.1 BREVIBLOC Injection Dosage Forms

    All BREVIBLOC injection presentations are clear, colorless to light yellow, sterile, nonpyrogenic, iso‑osmotic solutions of esmolol hydrochloride in sodium chloride. The formulations for BREVIBLOC PREMIXED Injection, BREVIBLOC PREMIXED Double Strength Injection, and BREVIBLOC Injection are described in the table below:

    Table 4 BREVIBLOC Injection Formulations

    BREVIBLOC PREMIXED Injection

    (Esmolol Hydrochloride)

    BREVIBLOC
    PREMIXED Double Strength Injection

    (Esmolol Hydrochloride)

    BREVIBLOC Injection

    (Esmolol Hydrochloride)

    Esmolol Hydrochloride, USP

    10 mg/mL

    20 mg/mL

    10 mg/mL

    Sodium Chloride, USP

    5.9 mg/mL

    4.1 mg/mL

    5.9 mg/mL

    Water for
    Injection, USP

    Q.S. to volume
    of 250 mL

    Q.S. to volume
    of 100 mL

    Q.S. to volume
    of 10 mL

    Sodium Acetate Trihydrate, USP

    2.8 mg/mL

    2.8 mg/mL

    2.8 mg/mL

    Glacial Acetic
    Acid, USP

    0.546 mg/mL

    0.546 mg/mL

    0.546 mg/mL

    Sodium Hydroxide

    Q.S. to adjust pH to 4.5-5.5

    Hydrochloric Acid

    Q.S. to adjust pH to 4.5-5.5

    Q.S. = Quantity sufficient

    The calculated osmolarity of BREVIBLOC PREMIXED Injection and BREVIBLOC DOUBLE STRENGTH PREMIXED Injection is 312 mOsmol/L. The 250 mL and 100 mL bags are non-latex, non-PVC INTRAVIA bags with dual PVC ports. The INTRAVIA bags are manufactured from a specially designed multilayer plastic (PL 2408). Solutions in contact with the plastic container leach out certain chemical compounds from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    BREVIBLOC (Esmolol Hydrochloride) injection is a beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. BREVIBLOC injection inhibits the beta1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta2 receptors located chiefly in the bronchial and vascular musculature.

    12.2 Pharmacodynamics

    Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of BREVIBLOC injection, showing reduction in heart rate at rest and during exercise, and attenuation of isoproterenol-induced increases in heart rate. Blood levels of BREVIBLOC injection have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10‑20 minutes. The acid metabolite of esmolol exhibits negligible pharmacological activity.

    In human electrophysiology studies, BREVIBLOC injection produced effects typical of a beta blocker: a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade Wenckebach cycle length.

    In patients undergoing radionuclide angiography, BREVIBLOC injection, at dosages of 200 mcg/kg/min, produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular ejection fraction and cardiac index at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg). During exercise, BREVIBLOC injection produced reductions in heart rate, rate pressure product and cardiac index which were also similar to those produced by propranolol, but BREVIBLOC injection produced a significantly larger fall in systolic blood pressure. In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min of BREVIBLOC injection produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At 30 minutes after the discontinuation of BREVIBLOC infusion, all of the hemodynamic parameters had returned to pretreatment levels.

    The relative cardioselectivity of BREVIBLOC injection was demonstrated in 10 mildly asthmatic patients. Infusions of BREVIBLOC injection 100, 200 and 300 mcg/kg/min produced no significant increases in specific airway resistance compared to placebo. At 300 mcg/kg/min, BREVIBLOC injection produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and BREVIBLOC injection was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic bronchospasm requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced bronchospasm. No adverse pulmonary effects were observed in patients with COPD who received therapeutic dosages of BREVIBLOC injection for treatment of supraventricular tachycardia (51 patients) or in perioperative settings (32 patients).

    12.3 Pharmacokinetics

    Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes.

    Using an appropriate loading dose, steady-state blood levels of BREVIBLOC injection for dosages from 50-300 mcg/kg/min are obtained within five minutes. Steady-state is reached in about 30 minutes without the loading dose. Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range. Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion. Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion.

    Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine. Within 24 hours of the end of infusion, the acid metabolite of esmolol in urine accounts for approximately 73-88% of the dosage.

    Metabolism of esmolol results in the formation of the corresponding free acid and methanol. The acid metabolite has been shown in animals to have negligible activity and in normal volunteers its blood levels do not correspond to the level of beta blockade. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. After a 4 hour maintenance infusion of 150 mcg/kg, the plasma concentrations of esmolol are similar in subjects with normal renal function and in patients with ESRD on dialysis. The half-life of the acid metabolite of BREVIBLOC injection, which is primarily excreted unchanged by the kidney, is increased about 12-fold to 48 hours in patients with ESRD. The peak concentrations of the acid metabolite are doubled in ESRD.

    Methanol blood levels, monitored in subjects receiving BREVIBLOC injection for up to 6 hours at 300 mcg/kg/min and 24 hours at 150 mcg/kg/min, approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity.

    BREVIBLOC injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.

  • 13 NONCLINICAL TOXICOLOGY

    Because of its short term usage no carcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol.

  • 14 CLINICAL STUDIES

    Supraventricular Tachycardia

    In two multicenter, randomized, double-blind, controlled comparisons of BREVIBLOC injection with placebo and propranolol, maintenance doses of 50 to 300 mcg/kg/min of BREVIBLOC injection were found to be more effective than placebo and about as effective as propranolol, 3‑6 mg given by bolus injections, in the treatment of supraventricular tachycardia, principally atrial fibrillation and atrial flutter. The majority of these patients developed their arrhythmias postoperatively. About 60-70% of the patients treated with BREVIBLOC injection developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less. The average effective dosage of BREVIBLOC injection was approximately 100 mcg/kg/min in the two studies. Other multicenter baseline-controlled studies gave similar results. In the comparison with propranolol, about 50% of patients in both the BREVIBLOC injection and propranolol groups were on concomitant digoxin. Response rates were slightly higher with both beta blockers in the digoxin-treated patients.

    In all studies significant decreases of blood pressure occurred in 20-50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The hypotension was symptomatic (mainly hyperhidrosis or dizziness) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. Hypotension was more common with BREVIBLOC injection (53%) than with propranolol (17%). The hypotension was rapidly reversible with decreased infusion rate or after discontinuation of therapy with BREVIBLOC injection. For both BREVIBLOC injection and propranolol, hypotension was reported less frequently in patients receiving concomitant digoxin.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    BREVIBLOC PREMIXED Injection

    • NDC: 10019-672-10, 2500 mg / 250 mL (10 mg/mL) Ready-to-use INTRAVIA Bags

    BREVIBLOC PREMIXED Double Strength Injection

    • NDC: 10019-668-10, 2000 mg / 100 mL (20 mg/mL) Ready-to-use INTRAVIA Bags

    BREVIBLOC Injection

    • NDC: 10019-115-01, 100 mg / 10 mL (10 mg/mL) Ready-to-use Vials, Package of 25

    16.2 Storage

    Store at 25˚C (77˚F). Excursions permitted to 15˚-30˚C (59˚-86˚F) [see USP Controlled Room Temperature]. Protect from freezing. Avoid excessive heat.

    Each bag contains no preservative. Once drug has been withdrawn from ready-to-use bag, the bag should be used within 24 hours, with any unused portion discarded.

    Visually inspect the container. If the administration port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired.

    Do not use plastic containers in series connections. Such use could result in an embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

    Do not remove unit from overwrap until ready to use. Do not use if overwrap has been previously opened or damaged. The overwrap is a moisture barrier. The inner bag maintains sterility of the solution. Tear overwrap at notch and remove premixed bag. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

    Check for minute leaks by squeezing the inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. Do not use unless the solution is clear (colorless to light yellow) and the seal is intact.

    Preparation for intravenous administration:

    • Use aseptic technique.
    • Suspend premixed bag from eyelet support.
    • Remove plastic protector from delivery port at bottom of bag.
    • Attach administration set.
    • Refer to complete directions accompanying set.
  • 17 PATIENT COUNSELING INFORMATION

    Physicians should inform patients of the risks associated with BREVIBLOC injection:

    • The most common adverse reactions are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension.

    Manufactured by

    Baxter Healthcare Corporation

    Deerfield, IL 60015 USA

    Baxter, Brevibloc, Brevibloc Premixed and Intravia are trademarks of Baxter International Inc.

    Novaplus is a registered trademark of Vizient, Inc.

    07-19-00-1676

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

    Brevibloc Representative Container Label 10019-668-10

    Container Label

    TO OPEN - TEAR NOTCH

    Do not remove unit from overwrap until ready to use.
    Do not use if overwrap has been previously opened or
    damaged.     The overwrap is a moisture barrier. The inner bag
    maintains the sterility of the product.
    NDC: 10019-668-10

    BREVIBLOC PREMIXED
    Double Strength
    Injection

    Esmolol Hydrochloride
    in Sodium Chloride
    2,000 mg/100 mL (20 mg/mL)

    100 mL

    Iso-Osmotic
    No Preservative Added
    Single Intravenous Use Only

    Each mL contains 20 mg Esmolol Hydrochloride USP, 4.1 mg Sodium
    Chloride USP in Water for Injection USP. Buffered with 2.8 mg Sodium
    Acetate Trihydrate USP, 0.546 mg Glacial Acetic Acid USP. pH adjusted
    with sodium hydroxide and/or hydrochloric acid.
    pH 5.0 (4.5 - 5.5).
    Sterile, nonpyrogenic.

    Rx only

    USUAL DOSAGE: See package insert.
    CAUTIONS: After removing the overwrap, check for leaks by
    squeezing container firmly. If leaks are found, discard as sterility may
    be impaired. Use only if solution is clear colorless to light yellow.
    Discard unused portion.
    DO NOT INTRODUCE ADDITIVES.
    Must not be used in series connections.
    Store at 25°C (77°F). Excursions permitted
    to 15    °-30°C (59°-86°F).
    [See USP Controlled Room Temperature.]
    PROTECT FROM FREEZING.
    Avoid excessive heat.

    novaplus logo

    Baxter logo
    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    For Product Inquiry 1 800 ANA DRUG
    (1-800-262-3784)

    2J1416
    07-07-00-0032
    2018/1

    Made in USA
    IntraVia Container
    Baxter, Brevibloc Premixed and IntraVia are
    trademarks of Baxter International Inc.

    Novaplus is a registered trademark of Vizient, Inc.

    BAR CODE POSITION
    ONLY
    310019668109

    Brevibloc Representative Carton Label 10019-668-10

    Carton Label

    10 x 100 mL Single Use
    NDC: 10019-668-10
    INTRAVIA containers
    BREVIBLOC PREMIXED
    Double Strength Injection
    Esmolol Hydrochloride in Sodium Chloride 2,000 mg/100 mL (20 mg/mL)
    Store at 25˚C (77˚F). Excursions permitted to 15˚-30˚C (59˚-86˚F).     [See USP
    C    ontrolled Room Temperature.] PROTECT FROM FREEZING. Avoid excessive heat.

    2D DATA
    MATRIX
    BAR CODE
    PLACEMENT
    ONLY

    Baxter, Brevibloc Premixed and IntraVia are
    trademarks of Baxter International Inc.

    Rx only

    (01)50310019668104
    (21)NNNNNNNNN
    (17)YYMMDD
    (10)XXXXXXX

    Code 2J1416
    For Product Inquiry
    1 800 ANA DRUG
    (1-800-262-3784)

    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    Made in USA
    475-345-00 07-06-00-0285

    EXP
    LOT

    BAR CODE PLACEMENT ONLY

    (01)50310019668104(21)NNNNNNNNNNNNNNNNNNNN(17)YYMMDD(10)XXXXXXXXX

    Brevibloc Representative Container Label 10019-672-10

    Container Label

    TO OPEN - TEAR NOTCH
    Do not remove unit from overwrap until ready to use.
    Do not use if overwrap has been previously opened or
    damaged.     The overwrap is a moisture barrier. The inner bag
    maintains the sterility of the product.
    NDC: 10019-672-10

    BREVIBLOC PREMIXED
    Injection

    Esmolol Hydrochloride
    in Sodium Chloride
    2,500 mg / 250 mL
    (10 mg/mL)

    250 mL

    Iso-Osmotic
    No Preservative Added
    Single Intravenous Use Only

    Each mL contains 10 mg Esmolol Hydrochloride USP, 5.9 mg Sodium
    Chloride USP in Water for Injection USP. Buffered with 2.8 mg Sodium
    Acetate Trihydrate USP, 0.546 mg Glacial Acetic Acid USP. pH adjusted
    with sodium hydroxide and/or hydrochloric acid.
    pH 5.0 (4.5 - 5.5).
    Sterile, nonpyrogenic.
    USUAL DOSAGE: See package insert.

    Rx only

    CAUTIONS: After removing the overwrap, check for leaks by squeezing
    container firmly. If leaks are found, discard as sterility may be impaired. Use
    only if solution is clear colorless to light yellow. Discard unused portion.
    DO NOT INTRODUCE ADDITIVES.
    Must not be used in series connections.
    Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F).
    [See USP Controlled Room Temperature.]
    PROTECT FROM FREEZING.
    Avoid excessive heat.

    novaplus logo

    Baxter logo
    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    For Product Inquiry 1 800 ANA DRUG
    (1-800-262-3784)

    2J1417
    07-07-00-0033
    2018/1

    Made in USA
    IntraVia Container
    Baxter, Brevibloc Premixed and IntraVia are trademarks of
    Baxter International Inc.

    Novaplus is a registered trademark of Vizient, Inc.

    BAR CODE POSITION
    ONLY
    310019672106

    Brevibloc Representative Carton Label 10019-672-10

    Carton Label

    10 x 250 mL Single Use
    NDC: 10019-672-10
    INTRAVIA containers
    BREVIBLOC PREMIXED Injection
    Esmolol Hydrochloride in Sodium Chloride
    2,500 mg/250 mL (10 mg/mL)
    Store at 25˚C (77˚F). Excursions permitted to 15˚-30˚C (59˚-86˚F).     [See USP
    C    ontrolled Room Temperature.] PROTECT FROM FREEZING. Avoid excessive heat.

    2D DATA
    MATRIX
    BAR CODE
    PLACEMENT
    ONLY

    Baxter, Brevibloc Premixed and IntraVia are
    trademarks of Baxter International Inc.

    Rx only

    (01)50310019672101
    (21)NNNNNNNNN
    (17)YYMMDD
    (10)XXXXXXX

    Code 2J1417
    For Product Inquiry
    1 800 ANA DRUG
    (1-800-262-3784)

    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    Made in USA
    475-344-00 07-06-00-0286

    EXP
    LOT

    BAR CODE PLACEMENT ONLY
    (01)50310019672101(21)NNNNNNNNNNNNNNNNNNNN(17)YYMMDD(10)XXXXXXXXX

  • INGREDIENTS AND APPEARANCE
    BREVIBLOC 
    esmolol hydrochloride injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 10019-668
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ESMOLOL HYDROCHLORIDE (UNII: V05260LC8D) (ESMOLOL - UNII:MDY902UXSR) ESMOLOL HYDROCHLORIDE20 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 4.1 mg  in 1 mL
    SODIUM ACETATE (UNII: 4550K0SC9B) 2.8 mg  in 1 mL
    ACETIC ACID (UNII: Q40Q9N063P) 0.546 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 10019-668-1010 in 1 CARTON01/31/2018
    1100 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01938612/31/1986
    BREVIBLOC 
    esmolol hydrochloride injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 10019-672
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ESMOLOL HYDROCHLORIDE (UNII: V05260LC8D) (ESMOLOL - UNII:MDY902UXSR) ESMOLOL HYDROCHLORIDE10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 5.9 mg  in 1 mL
    SODIUM ACETATE (UNII: 4550K0SC9B) 2.8 mg  in 1 mL
    ACETIC ACID (UNII: Q40Q9N063P) 0.546 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 10019-672-1010 in 1 CARTON01/31/2018
    1250 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01938612/31/1986
    Labeler - Baxter Healthcare Corporation (005083209)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation059140764ANALYSIS(10019-668, 10019-672) , LABEL(10019-668, 10019-672) , MANUFACTURE(10019-668, 10019-672) , PACK(10019-668, 10019-672) , STERILIZE(10019-668, 10019-672)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation194684502ANALYSIS(10019-668, 10019-672)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation001728059ANALYSIS(10019-668, 10019-672)

    • Trademark Results [BREVIBLOC]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    BREVIBLOC
    BREVIBLOC
    73433960 1287620 Live/Registered
    American Hospital Supply Corporation
    1983-07-08
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.